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Philippe Purnode, MD, cardiologist, Arrhythmia Unit of Brussels Heart Center, St.
John Clinic, Brussels, Belgium, external consultant cardiologist, Arrhythmia Unit,
Université Catholique de Louvain (UCL) Mont-Godinne Clinic, Yvoir, Belgium, and 
past-president of the Young Cardiologists’ Club, talks to Monika Polak, PhD. 


















Spotlight: Philippe Purnode, MD
“If the ATP Test Is Positive in a Patient Who Has Syncope of
Unknown Origin, We Implant a Pacemaker”
Thirty percent of syncope cases are of unknown cause,even after a complete diagnostic workup. However, a
recent article in Circulation suggests that adenosine
triphosphate (ATP) testing has a role in helping decide
which patients with syncope of unknown origin might ben-
efit from active dual-chamber pacing.1 The authors go on
to say that current European guidelines on syncope of
unknown origin,2 which suggest that use of the ATP test
should remain under investigation, should now be revisited.
Philippe Purnode, MD, external consultant cardiologist
in the Arrhythmia Unit, Université Catholique de Louvain
(UCL) Mont-Godinne Clinic, Yvoir, Belgium, and cardio -
logist in the Arrhythmia Unit of Brussels Heart Center, St.
John Clinic, specialises in rhythm electrophysiology and
was involved in the study. He says he has been using the
ATP test routinely in his clinical practice for some time. 
Dr Purnode explains, “In my practice, we usually use
the test to see whether a patient needs to be implanted with
a pacemaker. If the ATP test is positive (when we have an
asystole >10 seconds), we implant a pacemaker.” 
In the study, 80 patients (mean age 76 years) with
syncope of unknown origin and atrioventri -
cular/sinoatrial block >10 seconds under ATP administra-
tion had a programmable pacemaker implanted. They
were randomised to either active pacing (dual-chamber
pacing at 70 bpm) or backup pacing (atrial pacing at 30
bpm; control) and followed for up to 5 years (mean 16
months). Syncope recurred in 21 percent of those receiv-
ing active pacing compared with 66 percent of patients
receiving backup pacing (hazard ratio 0.25). Dr Purnode
says these results are comparable to those he sees in
everyday practice. 
“We Started a Programme to Ablate the Pulmonary
Vein at My Hospital 2 Years Ago”
Dr Purnode’s path into medicine and the decision to study
at UCL was in part influenced by his father, an endocrinol-
ogist, who had studied medicine at UCL. The proximity to
his home, ≈10 km away, also made it “very easy” to study
there. However, he did not follow his father into
endocrinology. He explains, “I am interested in the physi-
ology of the cardiac muscle. My professor who taught car-
diac physiology made it sound amazing. That was at the
beginning. I then wanted to do all my work in the cardiac
field.”
Dr Purnode completed his medical degree at UCL in
1995 and trained as a specialist in internal medicine at UCL
from 1995 to 1998. He then trained as a specialist in cardi-
ology from 1995 to 2002, working as a clinical assistant in
a variety of hospital clinics throughout this period. In 2002,
he was awarded first prize in internal medicine at UCL for
“cardiac resynchronisation therapy.” Also in 2002, he took
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up his present appointments of external consultant cardio -
logist in the Arrhythmia Unit, UCL Mont-Godinne Clinic,
and cardiologist in the Arrhythmia Unit of Brussels Heart
Center, St. John Clinic. 
Dr Purnode’s move into electrophysiology was driven
by Professor Luc De Roy, MD, one of the coauthors of the
Circulation study, who in 2002 was also based at UCL
Mont-Godinne. Under the guidance of Professor De Roy,
Dr Purnode learned more about arrhythmias, performing
electrophysiological studies and controlling implantable
cardioverter-defibrillators and pacemakers. He also partic-
ipated in numerous international, multicentre trials,
although the ATP study is his first article in a peer-reviewed
journal. He explains that when he was working as a fellow
in Professor De Roy’s Arrhythmia Unit, Professor De Roy
asked him to carry out the ATP test as part of the study
collaboration. Dr Purnode says, “Professor De Roy was a
good teacher and always has something good to say when
we look at an electrocardiogram with a problem.” The 2
continue to collaborate, sharing opinions on heart physio -
logy, heart disease, arrhythmias, and electrophysiology. Dr
Purnode has also been involved in developing atrial fibril-
lation ablation therapy at the Brussels Heart Center, St.
John Clinic. He says, “We started a programme to ablate
the pulmonary vein at my hospital 2 years ago, and I asked
Professor De Roy to help us. Everything is going well now.
I think we have a good collaboration with him, and I hope
we can continue for a long time.” At Brussels Heart Center,
St. John Clinic, Dr Purnode works with electrophysiolo-
gists Peter Goethals, MD, and Gaetano Paparella MD, as
well as Professor De Roy. 
Dr Purnode’s work at the Brussels Heart Center, St.
John Clinic takes up 80 percent of his time (the other 20
percent being spent at UCL Mont-Godinne). He is focused
on developing the Arrhythmia Unit and says, “I have plans
to do more with arrhythmia and aim to treat people with
arrhythmia problems correctly. That’s my goal.” Treating
patients is the most important aspect of his work, and he
finds the pulmonary vein ablation procedure particularly
rewarding. 
The Young Cardiologists’ Club: A Forum for “Sharing
Opinion With Other Young Cardiologists About the
Best Ways to Treat Patients”
In 2006, Dr Purnode became secretary of the Young
Cardiologists’ Club (see www.ycc.cardionet.be), a working
group of the Belgian Society of Cardiology for cardiolo-
gists working or training in Belgium who are <40 years of
age, which, Dr Purnode explains, “is all about sharing
opinion with other young cardiologists about the best
ways to treat patients.” He held the post for 2 years before
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Dr Purnode with his colleague Dr Goethals, the current secretary of
the Belgian Heart Rhythm Association. Photograph courtesy of Dr
Purnode.
Dr Purnode (right) with his mentor, Professor De Roy (left), and the nursing team in the electrophysiology lab, Brussels Heart Center.
Photograph courtesy of Dr Purnode.
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becoming president, from 2008 to 2010. He adds, ‘In the club,
we have people from the Dutch part and the French part.”
Founded in 1991, the Young Cardiologists’ Club is free
to join and aims to provide young cardiologists with an
opportunity to meet colleagues from other regions, and to
use this forum to express and develop new ideas in cardio -
logy. It is run by 4 board members—2 joint presidents (1
representing the French part of Belgium and 1 representing
the Dutch part), who also sit on the board of the Belgian
Society of Cardiology as representatives for the Young
Cardiologists’ Club, a treasurer, and a secretary. The cur-
rent presidents are Antoine Guedes, MD, who is based at
UCL Mont-Godinne, and Nico Van De Veire, MD, of Mary
Mediatrix General Hospital, Ghent, Belgium.
The Young Cardiologists’ Club also organises meet-
ings. As well as its quarterly meetings, during which atten-
dees discuss various issues or dilemmas relating to the
treatment of cardiac disease that they have encountered and
draw other members’ attention to findings from recently
published studies that they feel are particularly important,
the club organises an annual symposium (mainly the
responsibility of the presidents) to which international
speakers are invited. Previous topics have included sexual
dysfunction due to cardiac disease and uncommon car-
diomyopathy. This year’s symposium, to be held on
October 20 at the Van der Valk Airport Hotel in Brussels, is
titled “A Heart for Sports: Screening and Guidance for
Patients.” Speakers will include Professor Sanjay Sharma,
MD, consultant cardiologist at St. George’s Healthcare
NHS Trust, London, England, and Andre La Gerche, MD,
a cardiologist at St Vincent’s Hospital in Melbourne,
Australia.
In early spring each year, the Young Cardiologists’
Club holds a 3-hour “ECG Course for Dummies,” during
which young cardiologists are shown ECGs depicting
arrhythmias and asked to discuss the findings and present
a “solution.” 
The Young Cardiologists’ Club also organises purely
social weekend events for members and their families and
participates in occasional projects and initiatives. For
example, in 2007, in collaboration with a host of other
Belgian organisations, including the Belgian Society of
Cardiology, the Young Cardiologists’ Club was involved in
a public education campaign on the recognition of the early
signs of acute myocardial infarction, which involved devel-
oping posters, leaflets, and a website aimed at the general
public.
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The Young Cardiologists’ Club on a social event with their families. The club is a working group of the Belgian Society of Cardiology for
cardiologists <40 years of age who are working or training in Belgium and “is all about sharing opinion with other young cardiologists
about the best ways to treat patients.” Dr Purnode was president of the club from 2008 to 2010. Photograph courtesy of Dr Purnode.
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Based in Strasbourg, France, the Human FrontierScience Program (HFSP) supports innovative basic
research into fundamental biological problems with an
emphasis placed on novel approaches that involve scientific
exchanges across national and disciplinary boundaries.
Postdoctoral Long-Term Fellows
The HFSP awards international postdoctoral fellowships
for basic research training. These awards are aimed at sci-
entists with a PhD in a biological discipline to enable them
to embark on a new project in a different field of the life
sciences. Preference is given to applicants who propose an
original study in biology that marks a departure from their
previous PhD or postdoctoral work.
Kaaweh Molawi, PhD, 
postdoctoral fellow, Lab for
Stem Cell and Macrophage




Dr Molawi was awarded an
HFSP long-term fellowship in
2011. The 3-year grant started
in 2012 and covers his salary
and funds for research and
travelling. Together with Dr Sieweke, Dr Molawi aims to
delineate the subtype-specific functions of monocytes and
macrophages during cardiac tissue regeneration. The proj-
ect is being conducted in collaboration with the lab of
Nadia Rosenthal, PhD. Dr Molawi says, “The goal of this
analysis is to modulate the response of monocytes/ macro -
phages in a proregenerative direction and to improve func-
tional tissue regeneration.”
The researchers will take advantage of self-renewing
MafB/c-Maf double-deficient (Maf-DKO) macrophages
that have recently been developed and described by Dr
Sieweke’s lab. “Maf-DKO macrophages can be amplified
in culture without tumorigenic transformation while main-
taining functional macrophage identity,” explains Dr
Molawi. “Therefore these cells represent an ideal tool to
examine and manipulate monocyte/macrophage function
in the context of tissue regeneration.” The use of Maf-
DKO cells for factor delivery or for novel monocyte-medi-
ated cellular treatment strategies as an attractive alternative
to stem cell-based cell replacement therapies will also be
explored.
Before moving to Marseille, Dr Molawi worked at the
Max Planck Institute for Infection Biology in Berlin,
Germany, on the contribution of microglia-mediated
inflammation during neurodegeneration. He says, “This
work triggered my interest in the differential roles of myeloid




Lab, University of California,
San Francisco, CA
Dr Sawamiphak received her
HFSP long-term fellowship in
May 2011. She says, “The fel-
lowship provides me with not
only a living and research
allowance for 3 years, but also
a great opportunity to join
Professor Stainier’s lab in a resourceful working environ-
ment at the University of California, San Francisco.”
Previously, Dr Sawamiphak’s PhD study at Johann
Wolfgang Goethe University in Frankfurt, Germany, aimed
to elucidate the entwined network of signal transduction
that might bridge nerve wiring and sprouting angiogenesis.
Using various techniques to assess angiogenic sprouting at
the cellular and molecular levels, she found that the out-
growth of filopodial processes extended from specialised
tip cells that leads the directional migration of vascular
sprouts depends on ephrinB2, a well-known axonal guid-
ance cue. EphrinB2 acts in concert with the most promi-
nent angiogenic receptor, vascular endothelial growth fac-
tor receptor 2, to stimulate its endocytosis and thereby fine-
tune its downstream signalling required for the migratory
response of the endothelial tip cell. A similar mechanism is
also involved in cancer vascularisation.
“The funding I have received from the fellowship
allows me to pursue my interest in biomedical research as
well as acquire experience with a different model organism
to study human diseases,” says Dr Sawamiphak. She is
currently using zebrafish as a model system in a study
aimed at identifying novel cellular and molecular players
underlying the cross-talk between inflammatory response
and cardiac growth and regeneration. To this end, she has
been taking advantage of many attributes of the zebrafish,
including powerful genetic tools, body transparency suit-
able for in vivo imaging, and anatomical similarity with
higher vertebrates. She says, “My ultimate goal is a better
Scientists who have used Human Frontier Science Program awards for cardiovascular research
describe the award and their research to Jennifer Taylor, BSc, MSc, MPhil.
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understanding of the developmental and restorative pro-
gramme of the cardiovascular system to provide new











her 3-year HFSP long-term fellowship in February 2011.
The fellowship covers her salary and provides a travel
allowance. As a bioinformatician, Dr Ramialison’s main
focus of research is to model cardiac gene regulatory net-
works. She has also implemented the zebrafish model sys-
tem in the lab to experimentally validate the predictions
generated by the bioinformatics analysis. “I joined a mul-
tidisciplinary team of bioinformaticians and molecular
biologists to successfully reconstruct the gene regulatory
network driven by several cardiac transcription factors in
a wild-type and disease context,” she says. “Through the
bioinformatics predictions, we have discovered novel
genes implicated in heart development and unraveled
novel concepts in disease mechanisms.”
Dr Ramialison’s previous research at the Develop -
mental Biology Unit, European Molecular Biology Lab,
Heidelberg, Germany, was mainly focused on establishing
bioinformatics databases and tools to analyse the regula-
tion of synexpression groups during development. She also
examined specific synexpression groups using the medaka
fish as a model system.
Daniela Panáková, PhD,
junior group leader, 
Max Delbrück Center for
Molecular Medicine, 
Berlin-Buch, Germany
Dr Panáková held a HFSP
long-term fellowship from
2008 to 2011. It provided liv-
ing expenses and a research
and travel allowance to study
the coordination of early
embryonic function and pat-
terning of the vertebrate ven-
tricle in the group of Calum MacRae, MD, PhD, at Harvard
Medical School and Brigham and Women’s Hospital,
Boston, MA. They discovered that the patterning of the
gradient of electrical coupling requires noncanonical Wnt
signalling and demonstrated that Wnt11 modulates electri-
cal coupling through negative regulation of L-type Ca2+
channel conductance. Previously, as a PhD student in the
lab of Suzanne Eaton, PhD, at the Max Planck Institute of
Molecular Cell Biology and Genetics in Dresden,
Germany, Dr Panáková studied morphogen trafficking of
the lipid-linked morphogens Wingless and Hedgehog. It
had been proposed that these morphogens are transported
over long distances in the developing epithelia on particles
termed argosomes. “We were able to show that Drosophila
lipoprotein particles associate with Wingless, Hedgehog,
and a number of gpi-linked proteins,” says Dr Panáková.
“We proposed that lipoprotein particles act as vehicles for
their long-distance movement and are required for
Wingless and Hedgehog long-range signalling.” 
“In between my graduate studies and postdoctoral
work, I moved to a different area of research (from cell and
developmental biology to organogenesis and physiology)
and changed model organisms and continents,” says Dr
Panáková. “These are all assets required (among others) for
receiving a HFSP fellowship.” Dr Panáková adds, “The
travel allowance was instrumental in giving me flexibility
to connect and network with other scientists.”
Dr Panáková received a Helmholtz Young Investigator
Grant in 2010 and joined the Max Delbrück Center for
Molecular Medicine in Berlin-Buch, Germany, as a junior
group leader in 2011. 
Career Development Awards
The goal of HFSP Career Development Awards is to
encourage former HFSP long-term and cross-disciplinary
fellows to return to their home country to initiate an origi-
nal research programme in their own labs as independent
researchers. Candidates are encouraged to select research
institutions other than their PhD institute to facilitate their
scientific independence.
Jan Huisken, PhD, physicist,
Max Planck Institute of
Molecular Cell Biology and
Genetics, Dresden, Germany
Dr Huisken leads a Max
Planck research group that
works on organogenesis in
zebrafish with quantitative
microscopy and image pro-
cessing techniques. During his
PhD, he developed an innova-
tive fluorescence microscopy
technique called selective plane illumination microscopy.
“It turned out to be extremely useful for imaging the car-
diovascular system in small vertebrates such as zebrafish,”
he says. His postdoctoral work from 2005 to 2009 was pri-
marily funded by a cross-disciplinary HFSP fellowship,
which allowed him to optimise the technique and perform
experiments on the function and morphogenesis of the
zebrafish heart at the University of California, San
Francisco, in the lab of Professor Didier Stainier, PhD. He
and his colleagues were able to image fluctuating calcium
in the intact heart with high spatial and temporal resolution
and describe mechanisms of cardiac valve formation. 
Photo courtesy of David Ausserhofer.
© Max Delbrück Center.
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Selective plane illumination microscopy is not only
ideal for imaging sensitive samples such as living embryos
due to its speed and low phototoxicity, but it can also be
combined with innovative sample manipulation tech-
niques, eg, optogenetics. “My work at the University of
California, San Francisco, culminated in the development
of an optically controllable pacemaker in zebrafish,” says
Dr Huisken. “Using patterned illumination in our light
sheet microscope, we located the pacemaker and simulated
tachycardia, bradycardia, atrioventricular blocks, and car-
diac arrest.” 
Dr Huisken joined the Max Planck Institute in Dresden
in 2010 to continue working on the cardiovascular system
in zebrafish using home-built microscopes. A 3-year HFSP
Career Development Award is now supporting him to
investigate the embryonic zebrafish vasculature. The aim is
to create a detailed, dynamic atlas of the vasculature as a
first step to describe and quantify wild-type development
through high-resolution time-lapse image acquisition,
image processing, segmentation, and quantification. The
digital data are automatically annotated with blood flow
direction and speed, vessel diameter, and their hierarchy,
etc. “In a following step, this knowledge will be used to
identify and numerically describe novel vascular mutants
and quantify the effects of drugs,” he says. “The zebrafish
can thereby act as a model of human diseases and their
treatment.”
Julien Vermot, PhD, group
leader, Institute of Genetics
and Molecular and Cellular
Biology, Illkirch, France
Discoveries in the roles of
fluid forces during embryonic
development led to Dr Vermot
receiving an HFSP Career
Development Award in July
2010. With his colleagues in
the lab of Scott Fraser, PhD, at
California Institute of Techno -
logy, Pasadena, CA, he developed noninvasive methods to
probe flow in live embryos. First, they identified the flow
forces involved in controlling valvulogenesis during heart
development and a flow-responsive gene linking blood flow
and valve morphogenesis. Second, mixing classical approaches
in genetics with light imaging to address cilia-mediated
flow during development, they found that manipulating cilia
dynamics affects inner ear formation. The use of fast imag-
ing, optical tweezer, and mathematical modelling, uncov-
ered the mechanism of action of cilia during this process. 
The award provides €220 000 over 3 years, and Dr
Vermot is using it to run a lab, which includes 2 PhD students,
2 postdocs, 1 engineer, and 1 lab manager. Their goal is to
address the physical stimuli and molecular mechanisms
that specify cell responses to flow forces during cardiovas-
cular development. 
Dr Vermot’s group is located at the Institute of Genetics
and Molecular and Cellular Biology in Strasbourg, France,
and uses multidisciplinary approaches to address biological
blood flow functions during embryogenesis. “Moving
blood is a necessity for proper cardiovascular development.
We are particularly interested in understanding the relation-
ship between blood flow forces and tissue organisation in
the process of valvulogenesis and angiogenesis,” he says.
“We really enjoy interacting with physicists, engineers, and
mathematicians, as they help us develop new models,
approaches, and hypotheses related to the numerous roles





Dr Santoro received an HFSP
Career Development Award in
2008. It provided 3 years of
funding for salaries, instru-
ments, and reagents/dispos-
ables, which enabled him to
set up his own lab at the
University of Torino. His lab
uses the zebrafish model system to identify new molecular
mechanisms and pathways involved in the formation and
maturation of blood vessels, particularly focusing on
endothelial cells and vascular mural cells. Recently, they
described vascular smooth muscle cells in the zebrafish
during evolution, and they characterised, in collaboration
with another lab, the role of catepsin D during zebrafish
development. They have developed new techniques to
study microRNA functions in the cardiovascular system in
zebrafish, and, in collaboration with Pascal Meier, MD, in
London, England, they are further characterising the verte-
brate cIAP gene.
“Before obtaining the Career Development Award, I
had been working on cloning new zebrafish mutants with
specific cardiovascular development defects,” says Dr
Santoro. “I identified the tomato mutant, a null mutant of
cIAP1 with specific apoptotic defects in endothelial cells.
Later on, I was also involved in the characterisation of
microRNA functions in the zebrafish cardiovascular sys-
tem, in particular microRNA-126.”
Jennifer Taylor is a freelance medical journalist.
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